Skip to content
World Health Systems Facts

Italy: Pharmaceuticals

Health System Overview
Health System Rankings
Outcomes
Health System Coverage
Costs for Consumers
Health System Expenditures
Italy’s COVID-19 Policy

Health System Financing
Health System Personnel
Health System Physical Resources and Utilization
Long-Term Care
Health Information and Communications Technologies
Medical Training
Pharmaceuticals

Political System
Economic System
Population Demographics
People With Disabilities
Aging
Social Determinants & Health Equity
Health System History
Health System Challenges


Expenditure On Retail Pharmaceuticals Per Capita in US$ PPP, 2019: $659

Source: OECD (2021), Health at a Glance 2021: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/ae3016b9-en.


Expenditure On Retail Pharmaceuticals By Type Of Financing, 2019 (%)
Government/Compulsory Plans: 62%
Voluntary Health Insurance Plans: 0%
Out-Of-Pocket: 38%

Source: OECD (2021), Health at a Glance 2021: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/ae3016b9-en.


“In 2019, over 40 million people (around two thirds of the total population), of which 55% were women, received at least one pharmaceutical prescription corresponding to per capita expenditure of EUR 197 and a consumption ratio of 1,029 defined daily doses (DDD) per 1,000 inhabitants per day, suggesting that, on average, every Italian citizen received one dose of medication every day of the year. Total pharmaceutical expenditure – both public and private – amounted to EUR 30.8 billion, of which 76.4% was reimbursed by the SSN. OOP [Out Of Pocket] expenditure amounted to EUR 7.3 million and was mainly composed of Class C prescriptions (Table 5.4) (AIFA, 2020a).”

Source: de Belvis AG, Meregaglia M, Morsella A, Adduci A, Perilli A, Cascini F, Solipaca A, Fattore G, Ricciardi W, Maresso A, Scarpetti G. Italy: Health system review. Health Systems in Transition, 2022; 24(4): pp.i–203.


“The remuneration of community pharmacies (for medicines reimbursed by the SSN) is based on proportional margins in relation to the selling price. According to the latest legislation (Law 122/2010), margins for wholesalers and pharmacists are equal to 3.00% and 30.35%, respectively. Moreover, since 1997, there has been a progressive discount ranging from 3.75% to 19.00% according to the drug price bracket. There is also a further discount on the final price of the medicine, which has been equal to 2.25% since 2012 (Law 135/2012).

“Law 122/2010 also provided for a radical reform of the remuneration of pharmacies, establishing that it should be based on a fixed amount in addition to a reduced percentage of the drug’s reference price. An agreement between the Italian Medicines Agency (AIFA) and pharmacies associations was stipulated in October 2012 but not approved by the national government, and the deadline for the introduction of the new remuneration system has been postponed several times. At the time of writing, almost a decade later, there is no permanent agreement in place.

“An additional remuneration for pharmacists, equal to EUR 50 million for the year 2021 and EUR 150 million for 2022, was introduced on an experimental basis, starting from 1 September 2021 (Legislative Decree 41/2021). The new remuneration system should progressively enhance the professional role of pharmacists, based on the services provided to citizens and only partially linked to medicine prices. Indeed, the decree has introduced an extra fixed remuneration of EUR 0.08 for each medicine package (EUR 0.12 for generics).”

Source: de Belvis AG, Meregaglia M, Morsella A, Adduci A, Perilli A, Cascini F, Solipaca A, Fattore G, Ricciardi W, Maresso A, Scarpetti G. Italy: Health system review. Health Systems in Transition, 2022; 24(4): pp.i–203.


“Pharmaceutical distribution in Italy is one of the most complex in Europe and encompasses various actors:

“ƒ the manufacturer/marketing authorization holder, i.e. the company that produces the medicine and/or holds its marketing authorization;

“ƒ the carriers who are in charge of transport;

“ƒ the depositaries, logistic third parties who do not own the medicinesthey manage (and therefore do not bear the related business risk);

“ƒ the intermediate distributors, i.e. the wholesalers who own the pharmaceuticals they distribute and who have a legal obligation to fulfil the order within 12 hours; for this reason, they invest heavily in automation, innovation and technology;

“ƒ the dispensing points, which are the places where patients can pick up/buy the medicines, i.e. pharmacies, para-pharmacies, pharma corners in retail outlets such as supermarkets (introduced by Legislative Decree 223/2006, the so-called “Bersani Decree”, which liberalized the over-the-counter (OTC) medicines market),as well as local health authorities and hospitals.”

Source: de Belvis AG, Meregaglia M, Morsella A, Adduci A, Perilli A, Cascini F, Solipaca A, Fattore G, Ricciardi W, Maresso A, Scarpetti G. Italy: Health system review. Health Systems in Transition, 2022; 24(4): pp.i–203.


“Ceilings for reimbursable pharmaceutical spending in retail pharmacies were first introduced in 2001. These were initially capped at 13 % of total health expenditure per year at both national and regional levels, then reduced to 11 % in 2013 and to 8 % in 2017. In 2003, spending ceilings were also introduced for medicines delivered by hospital pharmacies for inpatients and outpatients. The ceilings for hospital pharmaceutical expenditure were initially set at 2.4 % of total health expenditure, but then increased to 3.5 % in 2013 and 6.9 % in 2017. These increases reflect the fact that new medicines used in hospitals are becoming more costly. For example, expenditure on cancer drugs increased by 12 % from 2016 to 2017, accounting for almost 23 % of total public pharmaceutical expenditure in the country in 2017 (AIFA, 2018).

“To avoid overspending, some agreements between industry, regions and the NHS have been established. If the ceiling on community pharmacy expenditure is exceeded, the industry (manufacturers and distributors) is liable to refund the excess spending to the NHS – a mechanism known as ‘pay-back’. If the hospital inpatient expenditure cap is exceeded, the regions and manufacturers are liable to refund 50 % each of the excess expenditure to the NHS.”

Source: OECD/European Observatory on Health Systems and Policies (2019), Italy: Country Health Profile 2019, State of Health in the EU, OECD Publishing, Paris/European Observatory on Health Systems and Policies, Brussels.


“To improve value for money in pharmaceutical spending, Italy has implemented a series of measures to promote greater use of generics. Unless a reason is provided by the doctor to preclude substitution, the pharmacist must mention to customers if a cheaper equivalent product exists. If the doctor indicates that the medicine is ‘not substitutable’ or if the customer insists on purchasing the brand name, the customer must pay the difference between the price of the dispensed medicine and the cheapest alternative.

“Between 2005 and 2017, the generics market share in Italy increased from 7 % to 25 % in volume (Figure 22). Nevertheless, the share remains well below the EU average, in part because pharmacists are remunerated according to a fixed percentage of the price of each product, which creates a disincentive for them to dispense (cheaper) generic medicines.”

Source: OECD/European Observatory on Health Systems and Policies (2019), Italy: Country Health Profile 2019, State of Health in the EU, OECD Publishing, Paris/European Observatory on Health Systems and Policies, Brussels.


Health Systems Facts is a project of the Real Reporting Foundation. We provide reliable statistics and other data from authoritative sources regarding health systems in the US and sixteen other nations.


Page last updated Feb. 7, 2023 by Doug McVay, Editor.

  • Home
  • About World Health Systems Facts
    • Contact Us
    • Join Our Email List
  • Breaking News & Opinion
  • Upcoming Events
  • Seventeen National Health Systems
    • Austria
    • Canada
    • Costa Rica
    • Czech Republic
    • Denmark
    • France
    • Germany
    • Hungary
    • Italy
    • Japan
    • Netherlands
    • South Korea
    • Spain
    • Sweden
    • Switzerland
    • United Kingdom
    • United States
  • Comparing National Health Systems
    • Healthcare Access and Quality Index
    • Sustainable Development Goals Health Index
    • Mirror Mirror 2021
    • World Health Report 2000
    • International Health Systems In Perspective
    • Lessons for US Health Reform
  • Aging
  • Health System Outcomes
  • Healthcare Spending
  • Healthcare Workers
    • Health System Personnel
    • Health Workforce Training
  • Information and Communications Technologies
  • Long-Term Services and Supports
  • People With Disabilities
  • Pharmaceutical Pricing and Regulation
  • Social Determinants & Health Equity
  • Wasteful Spending
  • Various US Health System Proposals
    • Affordable Care Act
    • All Payer
    • Public Option
    • Single Payer / “Medicare For All”
    • Universal Health Coverage
  • Recommended Resources
  • Privacy Policy
    • Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter

© 2019-2023 Real Reporting Foundation | Theme by WordPress Theme Detector

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
_GRECAPTCHA5 months 27 daysThis cookie is set by Google. In addition to certain standard Google cookies, reCAPTCHA sets a necessary cookie (_GRECAPTCHA) when executed for the purpose of providing its risk analysis.
cookielawinfo-checkbox-advertisement1 yearThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_UA-71314304-21 minuteThis is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.
_gcl_au3 monthsThis cookie is used by Google Analytics to understand user interaction with the website.
_gid1 dayThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
IDE1 year 24 daysUsed by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
test_cookie15 minutesThis cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
Powered by CookieYes Logo